In order to give more visibility to the characteristics of orphan drugs, AELMHU has developed the "Decalogue of Orphan Drugs", which aims to inform about the value of orphan drugs.
The Decalogue is summarised in the following points:
Ten points explaining, among other things, the specificity of orphan drugs, the Rare Diseases Strategy and its lines of action, the research and development process for these treatments, the role of the EMA, the Ministry and the autonomous communities, and the commitment of the pharmaceutical industry.
What are orphan drugs?
The National Strategy on Rare Diseases
The challenge of research and development of orphan drugs
The approval of such therapies
Access in Spain and in the Autonomous Communities
The commitment of the Pharmaceutical Industry